As a control, we showed that trametinib and ABT-263 had a negligible effect on normal CD34+ cell viability from two non-ALL individuals (Figure 4b), showing that this combination specifically targeted the leukemic cells while sparing normal hematopoietic cells. Here, CD34 is linked to acute lymphoblastic leukemia.